SV

Street Verdict

Analyst Scorecard

TARSONS · NSE

Tarsons Products Limited

₹303.4

-0.10% (-₹0.3)

Prev. close

₹303.7

Volume

1,00,811

Delivery %

16.6%

As of

20 Nov 2026

Price history

₹303.4-₹33.25 (-9.88%) · 3M
18 Aug 2026 → 20 Nov 2026
29030031032033034018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

No analyst stances in this range

0 analyst stances · last 90 days · one per analyst

Try a wider range.

Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions

Fundamentals

About Tarsons Products Limited

Tarsons Products Limited manufactures and trades in scientific plastic labware products in India and internationally. The company offers assay plates, biohazard and safetyware, bioprocessing solutions, bottles and carboys, boxes and racks, cell culture ware, centrifuge ware, clamps and stands, clinical and microbiology products, cryoware, desiccators, tubings and connectors, filtration products, general labware, genomics and PCR consumables, laboratory equipment, laboratory utilities, liquid handling consumables, liquid handling reusables, magnetic stirrer bars, PP storage plates, sampling aids, vials and tubes, and volumetric reusables. Its products are used in molecular biology, cell culture, genomics, proteomics, and immunology. Tarsons Products Limited was incorporated in 1983 and is headquartered in Kolkata, India.

Details

Sector

Healthcare

Industry

Medical Instruments & Supplies

CEO

Mr. Sanjive Sehgal

Headquarters

Kolkata

Employees

1,108

Key stats

Market cap

₹1,655.25 Cr

P/E ratio (TTM)

148.9

Dividend yield

0.00%

EPS (TTM)

₹2.09

Beta (1Y · daily vs NIFTY 50)

1.15

Beta (5Y · monthly vs NIFTY 50)

1.48

Shares float

1.05 Cr

EPS · quarter ended Jun 2026

₹-0.27

Financial Performance

01 · Financials

0 Cr200 Cr400 Cr600 Cr₹0%10%20%30%40%FY22FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

05101520₹FY22FY23FY24FY25FY26

03 · Dividend Profile

01122₹0%0.2%0.4%0.6%20 Sept 24
Dividend (₹/share)Annualised yield

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-50%0%50%100%FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

0 Cr500 Cr1000 Cr1500 Cr₹0×0.25×0.5×0.75×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr500 Cr1000 Cr1500 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

-200 Cr0 Cr200 Cr400 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
—₹300.79 Cr₹281.36 Cr₹296.39 Cr₹392.41 Cr₹422.51 Cr
EBITDA
—₹161.17 Cr₹141.62 Cr₹111.29 Cr₹126.69 Cr₹140.97 Cr
—₹100.66 Cr₹80.71 Cr₹42.64 Cr₹29.77 Cr₹14.32 Cr
Diluted EPS
—₹19.46₹15.17₹8.01₹5.6₹2.69

Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Net income, Pretax income, Tax provision, Interest expense, Other income, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹295.95 Cr₹544.23 Cr₹725.68 Cr₹972.18 Cr₹1,080.04 Cr₹1,185.82 Cr
₹33.50 Cr₹21.67 Cr₹110.69 Cr₹269.02 Cr₹339.17 Cr₹392.96 Cr
Stockholders' equity
₹244.34 Cr₹489.83 Cr₹569.30 Cr₹612.86 Cr₹630.21 Cr₹634.69 Cr

Fixed assets, CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
—₹83.47 Cr₹75.60 Cr₹102.71 Cr₹114.24 Cr₹118.48 Cr
Investing cash flow
—₹-137.95 Cr₹-178.55 Cr₹-284.95 Cr₹-145.49 Cr₹-130.37 Cr
—₹129.58 Cr₹84.56 Cr₹135.63 Cr₹38.95 Cr₹8.93 Cr
Capital expenditure
—₹-131.97 Cr₹-189.97 Cr₹-184.33 Cr₹-151.71 Cr₹-125.58 Cr
End cash position
₹2.33 Cr₹77.44 Cr₹59.06 Cr₹17.11 Cr₹25.13 Cr₹23.19 Cr

Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, Capital expenditure have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemNov 21–Dec 21(2Q)Mar 22–Sep 25(15Q)Dec 25–Jun 26(3Q)
Promoter47.30%47.31%47.30%
Public52.70%52.69%52.70%
Employee trusts0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Tarsons Products Limited₹1,548.30 Cr₹288.85139.22.442.3%0.62+7.7%-0.1%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

TARSONS

Tarsons export growth hit 37% as containers delayed shipments

Multibagg AI · 3 days ago

TARSONS

Tarsons Products Q2 FY27 Earnings Call Key Highlights

Kalkine India · 3 days ago